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Abstract
Background: We studied the distribution and expression of translocator protein in the human brain using 11C-[R]-
PK-11195 positron emission tomography (PK11195 PET) and evaluated age-related changes.
Methods: A dynamic PK11195 PET scan was performed in 15 normal healthy adults (mean age: 29 ±8.5 years
(range: 20 to 49); 7 males) and 10 children (mean age: 8.8 ±5.2 years (range: 1.2 to 17); 5 males), who were studied
for potential neuroinflammation but showed no focally increased PK11195 binding. The PET images were evaluated
by calculating standard uptake values and regional binding potential, based on a simplified reference region model,
as well as with a voxel-wise analysis using statistical parametric mapping.
Results: PK11195 uptake in the brain is relatively low, compared with the subcortical structures, and symmetrical.
The overall pattern of PK11195 distribution in the brain does not change with age. PK11195 uptake was lowest in
the frontal-parietal-temporal cortex and highest in the pituitary gland, midbrain, thalamus, basal ganglia, occipital
cortex, hippocampus and cerebellum, in descending order. White matter showed negligible PK11195 uptake.
Overall, brain PK11195 uptake increased with age, with midbrain and thalamus showing relatively higher increases
with age compared with other brain regions.
Conclusions: The brain shows low PK11195 uptake, which is lower in the cortex and cerebellum compared with
subcortical structures, suggesting a low level of translocator protein expression. There is no hemispheric asymmetry
in PK11195 uptake and the overall pattern of PK11195 distribution in the brain does not change with age. However,
brain PK11195 uptake increases with age, with the thalamus and midbrain showing relatively higher increases
compared with other brain regions. This increase in uptake suggests an age-related increase in translocator protein
expression or the number of cells expressing these receptors or both.
Keywords: Adults, Brain, Children, C-[R]-PK-11195 positron emission tomography, Glial cells, Inflammation, Microglia,
Neuroinflammation, PBR, Peripheral benzodiazepine receptor, PK11195 PET, Translocator protein, TSPO
Background
The 18 kDa translocator protein (TSPO), previously known
as the peripheral benzodiazepine receptor, is a hetero-
oligomeric complex comprising the voltage-dependent
anion channel as well as an adenine nucleotide carrier
found in both the periphery and the brain [1-4]. In the nor-
mal healthy brain, TSPO is located in ependymal cells li-
ning the ventricles, the olfactory bulb, the choroid plexus,
and glial cells, including astrocytes and microglia [5,6].
Microglia are mesoderm-derived brain macrophages and
represent the resident immunocompetent cells that become
activated during neuroinflammation [7]. In neuroinflamma-
tion, activated microglia are the primary source of TSPO
expression, with lower or insignificant contributions
from astrocytes [8]. This is the rationale for in vivo
imaging (detection) of neuroinflammation or underlying
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activated microglia using various radiotracers, which spe-
cifically bind to the TSPOs expressed by these activated
microglia.
The carbon-11 labeled positron emission tomography
(PET) tracer 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-
3-isoquinoline carboxamide (11C-[R]-PK-11195 (PK11195))
selectively binds to TSPOs and has been used most for
in vivo imaging of neuroinflammation [9]. However, ex-
perience with this tracer in children is very limited, and
detailed PK11195 brain PET kinetics and data about
age-related changes are lacking. The purpose of the
present study was to evaluate the brain distribution and
expression of TSPOs, using PK11195 brain PET, and to
evaluate the effect of age.
Methods
Participants
A total of 25 participants were recruited in this study:
15 normal healthy adults (mean age: 29 ± 8.5 years
(range: 20 to 49); 7 males) and 10 children (mean age:
8.8±5.2 years (range: 1.2 to 17); 5 males) in whom neuroin-
flammatory processes were being considered. Three of
these children had a diagnosis of partial epilepsy, three
children had encephalitis-like features without a firm
diagnosis, two children had motor tics, and two had
developmental delay and a history of dyskinesia. These
children were selected from a group of 93 children
who underwent a PK11195 PET scan due to suspected
neuroinflammation. In all these children, neuroinflam-
mation was eventually considered to be unlikely on the
basis of all available clinical, radiological, serological
and follow-up data, and no focal increase in PK11195
binding was detected in these children compared with
the normal adult control participants. We therefore
believe that this group of children likely represents a
relatively normal distribution of TSPOs in the pediatric
age group. All the participants had normal magnetic res-
onance imagining scans and none of the children were
taking any steroids, benzodiazepine or anti-inflammatory
drugs prior to the study.
All studies were performed in accordance with guidelines
stipulated by the Human Subjects Research Committee at
Wayne State University, Detroit, MI, USA, and written
informed consent was obtained from adult participants
and parents or guardians of the children. Oral or writ-
ten assent was obtained for children age 7 to 12 years
and 13 to 18 years, respectively.
Positron emission tomography imaging procedure
The PK11195 was produced using a synthesis module,
designed and built in-house [10]. PET studies were per-
formed using the CTI/Siemens EXACT/HR whole-body
positron tomograph (Siemens, Knoxville, TN, USA) after
6 hours of fasting. Prior to tracer injection, a 15-minute
transmission scan of the head was acquired using rotat-
ing Ge-68 line source to correct for attenuation correc-
tion. Coinciding with the tracer injection (17 MBq/kg), a
60-minute dynamic scanning of the brain was initiated
(12 × 5 minutes). Emission data were acquired in three-
dimensional mode and measured attenuation correction
as well as scatter and decay correction were applied to
all PET images. The reconstructed image resolution was
6.5 ± 0.3 mm full-width at half maximum in-plane and
6.0 ± 0.5 mm full-width at half maximum in the axial dir-
ection. Eight children required sedation, which was per-
formed using intravenous nembutal (3 mg/kg), as it has
been reported that acute short-term use of barbiturate
does not affect TSPO receptors [11].
Positron emission tomography image processing and
analysis
PET images were evaluated both qualitatively (visu-
ally) as well as quantitatively based on the calculation
of standard uptake values (SUVs), reflecting overall
PK11195 uptake, and binding potential (BP), reflecting
specific PK11195 binding to TSPO receptors. Moreover,
all images were also analyzed using a voxel-wise ana-
lysis of whole-brain PK11195 PET data using a statis-
tical parametric approach.
Visual analysis
Initially, the dynamic image sequence was averaged be-
tween 5 and 20 minutes post injection and normalized
to the injected dose per participant weight as follows:
(μCi/cm3)/(injected activity/weight). This yieldsed semi-
quantitative SUV images that were visually assessed. The
time interval between 5 and 20 minutes was chosen, as
this time period represented the highest tracer activity ac-
cumulation, excluding the perfusion phase (see Figure 1),
and provided the best image quality.
Calculation of standard uptake value and binding potential
Regions of interest encompassing various brain regions
were defined manually in the SUV images and corre-
sponding time-activity curves (TACs) were generated
from the whole dynamic sequence. To compare TACs
across participants, all TACs were normalized to the
injected dose per participant weight using the formula
above, which numerically corresponds to the SUV values
at various time points. The normalized TACs were sub-
sequently used to calculate SUV (from 5 to 20 minutes)
and the regional BP (using complete dynamic data set),
based on a simplified reference tissue model [12]. In the
reference tissue model, the time course of the tracer in
the region of interest is expressed in terms of the tracer
uptake in a reference region devoid of specific binding.
It is further assumed that the level of nonspecific bind-
ing is equal in the region of interest and the reference
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region. The time course of the PK11195 in the region of
interest CROI(t) can then be expressed as
CROI tð Þ ¼ R1Cref tð Þ þ k2  R1k21þ BP
 
Cref tð Þ k2te1 þ BP
where Cref (t) is the time course of tracer activity in
the reference region and R1 (the ratio of delivery of
the tracer between the target and reference region),
k2 (the efflux rate constant from the target tissue)
and BP are the parameters to be estimated using
nonlinear fitting. Of specific interest for the PK11195
is the BP which characterizes the ratio between the
association and dissociation constants of the ligand-
receptor complex. As the brain region completely de-
void of specific binding is not known with certainty,
the TAC for the reference region was created using a
cluster analysis approach [13]. In brief, voxels were ini-
tially constrained to gray matter and this subset of voxels
was subsequently segmented into nine clusters, character-
ized by the maximal value and the shape of the correspond-
ing TACs. The cluster characterized by the TACs with
lowest maximal value and fastest washout was subsequently
used as the reference tissue, as they were considered to be
Figure 1 Normalized time activity curves. Normalized time activity curves from various brain regions showing rapid 11C-[R]-PK11195 uptake
followed by steady washout. Triangles: adults (≥18 years of age); squares: children (<18 years of age); SUV: standard uptake value.
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devoid of any specific binding. These clusters were
found to be located in the frontal-temporal-parietal cortex,
as these regions showed the lowest PK11195 uptake,
both quantitatively (Figure 1 and Tables 1 and 2) and
qualitatively (Figure 2).
Voxel-wise analysis (statistical parametric mapping)
Voxel-wise analysis of SUV images was performed to
assess the global differences in PK11195 uptake be-
tween adults (≥18 years of age; n = 15) and children
(6 to 18 years of age; n = 8), as we have previously
shown the feasibility of statistical parametric mapping
(SPM) analysis using an adult template [14]. The ana-
lysis was performed using SPM8 software package
(Wellcome Department of Cognitive Neurology, Institute
of Neurology, London, UK). Spatial normalization was
performed using (7 × 8 × 7) number of basis functions
with medium regularization, 12 nonlinear iterations and a
smoothing kernel of 16 mm, resulting in an image
resolution of approximately 18 mm full-width at half
maximum. Subsequently, to analyze regionally specific
effects, a general linear model was used to assess differ-
ences among parameter estimates (specified by contrasts)
and the significance of individual contrasts was then
tested using the SPM(t) statistics for each voxel. The
confounding effect of global activity was removed
using proportional scaling and a two-sample t-test
was applied, with the resulting SPM(t) thresholded
at P <0.05 (corrected for family-wise error) with a
cluster threshold of 20 voxels.
Statistical analysis
Values are expressed as mean ±SD. The Spearman’s
correlation analysis was performed to assess the cor-
relation of age with BP or SUV and a repeated measure
analysis of variance (ANOVA) was performed to assess
hemispheric asymmetry. A mixed-design ANOVA was
performed to evaluate any difference between children
(<18 years of age) and adults (≥18 years of age) with
respect to side (left/right) and brain region, without in-
cluding the pituitary, which was analyzed separately. This
was followed by a simple effect test to compare the differ-
ence in any specific brain region. A P-value less than 0.05
was considered significant. The SPSS program (version
18.0; SPSS Inc.) was used for the statistical analyses.
Results
Visual analysis
SUV images of PK11195 in the brain of a child and an adult
control are shown in Figure 2. The overall brain PK11195
Table 1 Standard uptake value of 11C-[R]-PK11195 in various brain regions
SUV5 to 20 minutes (mean ± SD (95% CI))
Side Adults (n = 15) Children (n = 10) P
Pituitary gland 1.04 ±0.19 (1.27 to 1.53) 1.01 ±0.43 (0.60 to 2.09)a 0.97
Midbrain 1.11 ±0.17 (1.01 to 1.2) 0.9 ±0.21 (0.75 to 1.01) 0.001
Thalamus Left 1.09 ±0.14 (1.01 to 1.17) 0.84 ±0.23 (0.67 to 1) 0.002
Right 1.08 ±0.12 (1.02 to 1.15) 0.84 ±0.24 (0.67 to 1.01) 0.002
Lentiform nucleus Left 1.0 ±0.12 (0.94 to 1.07) 0.78 ±0.19 (0.65 to 0.92) 0.002
Right 0.97 ±0.15 (0.89 to 1.05) 0.76 ±0.2 (0.62 to 0.91) 0.006
Caudate Left 0.93 ±0.11 (0.87 to 0.99) 0.73 ±0.17 (0.61 to 0.85) 0.001
Right 0.92 ±0.11 (0.86 to 0.99) 0.73 ±0.17 (0.60 to 0.85) 0.002
Hippocampus Left 0.88 ±0.11 (0.82 to 0.94) 0.69 ±0.17 (0.57 to 0.81) 0.002
Right 0.87 ±0.11 (0.81 to 0.93) 0.69 ±0.16 (0.57 to 0.81) 0.002
Cerebellum Left 0.97 ±0.11 (0.91 to 1.03) 0.77 ±0.2 (0.63 to 0.91) 0.003
Right 0.99 ±0.12 (0.92 to 1.05) 0.76 ±0.20 (0.62 to 0.90) 0.001
Frontal cortex Left 0.95 ±0.11 (0.88 to 1.01) 0.73 ±0.17 (0.61 to 0.86) 0.001
Right 0.94 ±0.11 (0.88 to 1.00) 0.73 ±0.17 (0.61 to 0.85) 0.001
Parietal cortex Left 0.87 ±0.11 (0.81 to 0.93) 0.68 ±0.17 (0.56 to 0.8) 0.002
Right 0.87 ±0.11 (0.81 to 0.93) 0.68 ±0.17 (0.56 to 0.8) 0.002
Temporal cortex Left 0.86 ±0.10 (0.80 to 0.92) 0.68 ±0.17 (0.55 to 0.8) 0.002
Right 0.85 ±0.11 (0.79 to 0.91) 0.68 ±0.16 (0.56 to 0.8) 0.005
Occipital cortex Left 0.91 ±0.11 (0.85 to 0.98) 0.68 ±0.19 (0.54 to 0.82) 0.001
Right 0.88 ±0.09 (0.82 to 0.93) 0.69 ±0.19 (0.55 to 0.82) 0.003
aPituitary SUV values available in three children only, as it could not be estimated in seven children because of an inability to reliably delineate the pituitary from
the surrounding lymphoid tissue/circular venous plexus in these children. CI confidence intervals; SD standard deviation; SUV standard uptake value.
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Table 2 Binding potential values of 11C-[R]-PK11195 in various brain regions
Binding potential (mean ± SD (95% CI))
Side Adults (n = 15) Children (n = 10) P
Pituitary gland 0.62 ±0.18 (0.49 to 0.75) 0.61 ±0.19 (0.15 to 1.07)* 0.95
Midbrain 0.45 ±0.09 (0.38 to 0.48) 0.41 ±0.08 (0.40 to 0.48) 0.09
Thalamus Left 0.35 ±0.04 (0.33 to 0.37) 0.28 ±0.13 (0.19 to 0.37) 0.08
Right 0.34 ±0.07 (0.30 to 0.37) 0.29 ±0.12 (0.21 to 0.37) 0.20
Lentiform nucleus Left 0.20 ±0.05 (0.17 to 0.23) 0.19 ±0.07 (0.14 to 0.24) 0.63
Right 0.15 ±0.05 (0.12 to 0.18) 0.15 ±0.07 (0.09 to 0.21) 0.92
Caudate Left 0.10 ±0.05 (0.07 to 0.13) 0.08 ±0.06 (0.03 to 0.13) 0.45
Right 0.09 ±0.04 (0.07 to 0.12) 0.08 ±0.05 (0.01 to 0.14) 0.46
Hippocampus Left 0.11 ±0.04 (0.07 to 0.14) 0.07 ±0.04 (0.03 to 0.12) 0.20
Right 0.10 ±0.06 (0.06 to 0.14) 0.10 ±0.06 (0.04 to 0.15) 0.83
Cerebellum Left 0.10 ±0.04 (0.07 to 0.12) 0.08 ±0.03 (0.05 to 0.11) 0.45
Right 0.09 ±0.04 (0.07 to 0.11) 0.07 ±0.03 (0.05 to 0.10) 0.24
Frontal cortex Left 0.06 ±0.03 (0.04 to 0.07) 0.05 ±0.01 (0.04 to 0.06) 0.47
Right 0.05 ±0.03 (0.03 to 0.07) 0.05 ±0.03 (0.03 to 0.07) 0.85
Parietal cortex Left 0.04 ±0.03 (0.02 to 0.05) 0.03 ±0.02 (0.01 to 0.04) 0.64
Right 0.04 ±0.01 (0.03 to 0.05) 0.04 ±0.03 (0.02 to 0.06) 0.53
Temporal cortex Left 0.05 ±0.03 (0.03 to 0.07) 0.05 ±0.02 (0.03 to 0.07) 0.85
Right 0.05 ±0.02 (0.03 to 0.06) 0.02 ±0.02 (0.03 to 0.07) 0.91
Occipital cortex Left 0.11 ±0.05 (0.08 to 0.14) 0.11 ±0.04 (0.08 to 0.13) 0.79
Right 0.12 ±0.03 (0.10 to 0.14) 0.12 ±0.02 (0.10 to 0.13) 0.88
*Pituitary binding potential values available in three children only, as it could not be estimated in seven children because of an inability to reliably delineate the
pituitary from the surrounding lymphoid tissue/circular venous plexus in these children. CI confidence intervals; SD standard deviation.
Figure 2 Images of 11C-[R]-PK11195 brain positron emission tomography scan. PK11195 brain PET scan showing PK11195 brain distribution
in a child (upper row) and healthy normal adult (lower row). The overall brain PK11195 uptake is relatively low, suggested by much lower cortical
PK11195 uptake compared to subcortical structures, and the pattern of PK11195 distribution is largely similar in both children and adults,
although PK11195 uptake appears to be visually slightly higher in adults, particularly in the thalamus and midbrain. Highest PK11195 uptake is
noted in the pituitary gland and midbrain, followed by thalamus, basal ganglia, occipital cortex, hippocampus and cerebellum. The rest of the
cerebral cortex is showing low PK11195 uptake with minimal uptake in white matter. BG: basal ganglia; MB: midbrain; Cer: cerebellum; Cg:
cingulum; F: frontal cortex; Hip: hippocampus; P: parietal cortex; Pit: pituitary gland; T: temporal cortex; Th: thalamus; R: right side; L: left side.
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uptake was relatively low, suggested by much lower cortical
PK11195 uptake compared with subcortical structures as
evidenced by both quantitative (Tables 1 and 2) and qualita-
tive (visual; Figure 2) data. The pattern of PK11195 distri-
bution was similar in both children and adults, although
PK11195 uptake appeared to be visually slightly higher in
adults. Visual assessment showed highest PK11195 uptake
in the pituitary gland and midbrain, followed by thalamus,
basal ganglia, occipital cortex, hippocampus and cerebel-
lum. By contrast, the rest of the cerebral cortex showed low
PK11195 uptake with minimal uptake in white matter.
Standard uptake values analysis
Normalized TACs (for injected dose and participant
weight) for most brain regions showed rapid increase of
tracer, reaching a peak within 1 to 2 minutes of tracer
injection followed by a steady washout, with TACs being
lower in children compared with adults (Figure 1). Con-
sistent with the visual appearance, the highest tracer up-
take (SUV) was observed in the pituitary gland followed
by the midbrain, thalamus, basal ganglia, hippocampus
and cerebellum, with the lowest uptake seen in the frontal,
parietal and temporal cortices (Table 1). The occipital cor-
tex displayed the highest SUV among cortical structures;
however, this region also showed the most rapid washout.
No left-right asymmetry was observed for SUV values.
SUVs for all brain regions showed a very significant posi-
tive correlation with age (Figure 3) and were found to be
significantly higher in adults than in children (Table 1).
Binding potential analysis
BP analyses were consistent with visual and SUV analyses,
with the highest BP being determined in the pituitary gland
and midbrain followed by thalamus and basal ganglia, and
the lowest BP in cortical areas (Table 2). PK11195 binding
in the cerebellum was found to be higher than that in the
frontal-parietal-temporal cortex. No left-right asymmetry
was detected for any of the tested brain regions. However,
unlike the SUVs, there was no significant correlation be-
tween BP values and age, except for thalamus which
showed a trend (P=0.09).
Voxel-wise analysis
SPM analysis of SUV images, carried out between adult
and children, showed significantly higher PK11195 SUV in
adults in the region of the thalamus and the midbrain only
(P=0.001, corrected), suggesting a relatively higher age-
related increase in thalamic and midbrain PK11195 SUV
compared with other brain regions (Figure 4). There were
no statistically significant differences determined for the
cortex, basal ganglia or cerebellum.
Discussion
The results of our study show that brain PK11195 uptake
is low with the overall pattern of PK11195 brain distribu-
tion not changing with age. The PK11195 uptake was
found to be lowest in the frontal-parietal-temporal cortex
and highest in the pituitary gland, midbrain and thalamus.
Intermediate tracer uptake was determined in the basal
ganglia, occipital cortex, hippocampus and cerebellum, in
descending order. We did not observe any hemispheric
asymmetry in PK11195 uptake. However, overall PK11195
uptake increased with age, with the thalamus and mid-
brain showing relatively higher increases compared with
other brain regions. Interestingly, we did not find similar
significant age-related changes in BP values, except for the
thalamus, which showed a trend. The differences in age-
related changes between the SUV and BP may be be-
cause BP calculation depended on reference region
uptake values, and a generalized whole-brain increase
in PK11195 uptake, including the ‘reference region’
(See Figure 3), might have rendered BP values largely
unchanged, except for the thalamus, where a relatively
higher increase in PK11195 uptake resulted in a trend
toward statistical significance.
Our findings indicate that, in the brain, there is a rela-
tively low level of TSPO expression, which increases with
age, probably due to an increase in TSPO number and/or
expression, an increase in cells containing these receptors,
or both. Moreover, TSPO expression is lowest in the cortex,
particularly in the frontal, parietal and temporal cortices,
and highest in the pituitary gland and midbrain, followed
by thalamus, basal ganglia, hippocampus and cerebellum.
Most importantly, the TSPO distribution pattern remains
unchanged with increasing age, being largely similar in chil-
dren and adults, and no hemispheric asymmetry is seen in
the pattern or level of TSPO expression.
The observed PK11195 binding pattern in the present
study is consistent with the normal brain TSPO distri-
bution described in the literature [5,6,15]. Age-related
increases in microglia and upregulation of TSPOs have
been reported in several animal, human and postmor-
tem studies [16-23]. It appears that aging may serve as
a priming stimulus for microglia [24], and ontogenic
changes in TSPOs, related to increase in glial cells, have
been reported in rat and guinea pig brain [25-27]. Signifi-
cantly greater numbers of microglia and astrocytes were
reported in the hippocampus of aged female mice [28], and
an age-related increase in the expression of a microglia-
associated antigen was reported in rat and monkey brain
[29,30]. In a human postmortem study, an age-related in-
crease in the number of enlarged and especially phagocytic
microglia was found in the brain of neurologically normal
individuals, aged 2 to 80 years [31]. It appears that these
age-related changes may be due to chronic and persistent
neuronal damage over the years, shown to occur in the
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Figure 3 Effect of age on brain 11C-[R]-PK11195 uptake. Correlation analysis between age and PK11195 uptake (standardized uptake value;
SUV) showed a significant age-related increase in brain PK11195 uptake.
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brains of experimental animals [32]. Age-related oxidative
damage to DNA, more for mitochondrial than for nuclear
DNA [33], and accumulation of glycated proteins occurs
in normal aging human brain [34]. These changes lead
to microglial activation, which is considered to be in-
strumental in the removal of such damage and routine
‘house-cleaning’. Therefore, an age-related increase in
brain PK11195 uptake as seen in the present study is
likely related to the age-related increase in activated
microglia and increased TSPO expression.
We also found that the age-related increase in PK11195
uptake was higher in the thalamus and midbrain com-
pared with other cortical and subcortical regions, which is
consistent with a finding reported previously in an older
adult group [35]. In a study of normal adults aged 32 to
80 years, Cagnin et al. found that regional PK11195 BP did
Figure 4 Result of voxel-based analysis of 11C-[R]-PK11195 positron emission tomography scans. Voxel-wise statistical parametric
mapping analysis of PK11195 standard uptake value images, carried out between adults and children, showed significantly higher PK11195
uptake in adults in the thalamus and midbrain region only.
Kumar et al. Journal of Neuroinflammation 2012, 9:232 Page 8 of 10
http://www.jneuroinflammation.com/content/9/1/232
not significantly change with age, except in the thal-
amus, which showed an age-dependent increase [35].
The thalamus is connected to widespread cortical regions.
Similarly, the midbrain is reciprocally connected to several
brain regions, primarily the thalamus and basal ganglia,
and has one of the highest densities of microglia, particu-
larly in the substantia nigra [36]. Any subtle injury in va-
rious brain regions, as seen with normal aging, may induce
a similar but cumulative and amplified microglial response
in the thalamus and midbrain, leading to increased num-
ber of TSPOs and therefore increased PK11195 binding
[37,38]. This activation may facilitate remodeling, which is
an adaptive process in long-term plasticity in response
to progressive age-related neuronal loss. Further synap-
tic reorganization, most likely a compensatory response
to the decline in age-related brain function associated
with the reduction in functional integration across the
distributed neuronal network (including the thalamus
and midbrain), may induce progressively increased micro-
glial activation and proliferation. It is interesting to note
that enhanced age-related microglial activation in the
midbrain, triggered by various insults and leading to
inflammation-derived oxidative stress and cytokine-
dependent toxicity, may contribute to nigrostriatal path-
way degeneration and hasten progression of disease
in idiopathic Parkinson’s disease [39]. Indeed, mark-
edly elevated neuroinflammation has been reported
in the pons along with several other brain regions in
patients with idiopathic Parkinson’s disease com-
pared with age-matched healthy controls [40]. There-
fore, our findings of a higher age-related increase in
PK11195 uptake in the midbrain may be reflective of
an age-related increase in microglial activation that,
beyond a threshold, depending upon the type and
severity of noxious stimuli or insults, may result in
some neurological impairment. However, there may
be other possible explanations that need to be eluci-
dated and explored in future studies.
A few adult studies have reported PK11195 BP values
in several brain regions based on similar methodology,
and our values are largely consistent with these studies
[35,41]. However, no study is available regarding the
pediatric population, and detailed PK11195 brain
PET kinetics and data about age-related changes is
lacking. We believe that our study fills the existing
knowledge gap and provides important information
about PK11195 brain kinetics in the maturing brain
and age-related changes in TSPO distribution. Our
data will also assist in the interpretation and analysis
of PK11195 PET scans in various neuroinflammatory
conditions, especially in the pediatric population. The
present study also suggests that SPM analysis can be
useful for the evaluation of global cortical differences
in PK11195 uptake.
Limitations
One of the limitations of this work is the selection of a
reference region for the calculation of BP, and as a result
the calculated BP values may not be the true estimate of
actual receptor ligand binding. Ideally, arterial sampling
should be performed to obtain the true input function;
however, it is not practical in routine clinical work, par-
ticularly in the pediatric population. A cluster analysis
may be a reasonable compromise to obtain an estimate
of a reference region as a substitute for the true input
function, but this approach is only valid in the case where
the whole brain is not expected to be uniformly involved
in the neuroinflammatory process. Overall visual and SUV
analysis may help in these cases.
Another limitation is the selection of children; al-
though we recruited only those children in whom focal
neuroinflammation was ruled out, they were not com-
pletely healthy children. It is difficult to recruit com-
pletely ‘normal’ children because of ethical constraints
in exposing children to the radiation associated with
PET studies. Further, allowing for the fact that a few of
our children might have had subtle neuroinflammation
or some other conditions which might have led to
increased PK11195 uptake, completely normal children
would be expected to have even lower PK11195 uptake
values than observed here, and therefore will further
enhance and strengthen our finding of age-related increases
in brain PK11195 uptake. It is worth noting, however, that
age-related changes observed in the pediatric age-range
may not be completely representative due to possible
differences in the level of neuroinflammation in these
children, if any. It also infers that the normal pediatric
PK11195 values should be equal to or less than the nor-
mal adult values and, as a result, pediatric PK11195
values that exceed adult values can be safely considered
to be abnormal. This information has a practical impli-
cation for future studies using PK11195 PET in chil-
dren, where only normal adult PK11195 data may be
available for comparison purpose.
Conclusions
The brain shows low PK11195 uptake, lower in the cor-
tex and cerebellum compared with subcortical struc-
tures, suggesting low level of TSPO expression. There is no
hemispheric asymmetry in PK11195 uptake and the overall
pattern of PK11195 distribution in the brain does not
change with age. However, brain PK11195 uptake increases
with age, with the thalamus and midbrain showing rela-
tively higher increases compared with other brain regions,
suggesting an age-related increase in TSPO expression or
the number of cells expressing these receptors, or both.
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